A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
The Yellow Fever Vaccine 17D (YFV17D) has been used as a vector for the Lassa virus glycoprotein precursor (LASV-GPC) resulting in construction of YFV17D/LASV-GPC recombinant virus. The virus was replication-competent and processed the LASV-GPC in cell cultures. The recombinant replicated poorly in guinea pigs but still elicited specific antibodies against LASV and YFV17D antigens. A single subcutaneous injection of the recombinant vaccine protected strain 13 guinea pigs against fatal Lassa Fever. This study demonstrates the potential to develop an YFV17D-based bivalent vaccine against two viruses that are endemic in the same area of Africa.
Bredenbeek
Peter J
PJ
Department of Medical Microbiology, Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Molenkamp
Richard
R
Spaan
Willy J M
WJ
Deubel
Vincent
V
Marianneau
Phillippe
P
Salvato
Maria S
MS
Moshkoff
Dmitry
D
Zapata
Juan
J
Tikhonov
Ilia
I
Patterson
Jean
J
Carrion
Ricardo
R
Ticer
Anysha
A
Brasky
Kathleen
K
Lukashevich
Igor S
IS
D000818:Animals; D006023:Glycoproteins / Q000235:genetics / Q000378:metabolism*; D006168:Guinea Pigs; D006801:Humans; D007835:Lassa Fever / Q000517:prevention & control*; D007836:Lassa virus / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism; D015004:Yellow Fever / Q000517:prevention & control; D022341:Yellow Fever Vaccine / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism; D015005:Yellow fever virus / Q000276:immunology
D006023:Glycoproteins; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; D022341:Yellow Fever Vaccine